<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228136</url>
  </required_header>
  <id_info>
    <org_study_id>ISCMPA02</org_study_id>
    <nct_id>NCT01228136</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid and Pediatric Adenotonsillectomy</brief_title>
  <official_title>Use of Tranexamic Acid for Bleeding Reduction in Adenotonsillectomy in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Irmandade Santa Casa de Misericórdia de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Irmandade Santa Casa de Misericórdia de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the use of tranexamic acid prior
      adenotonsillectomy in children can reduce surgical and postoperative bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tonsillectomy with or without adenoidectomy is the most common major surgical procedure
      performed in children. Although it's a relatively simple procedure, may present complications
      as hemorrhage and death. The mortality associated to the surgery range between 1/1.000 and
      1/27.000 in the literature, with approximately 30% due to hemorrhage.

      Tranexamic acid is an antifibrinolytic hemostatic indicated to control bleeding in cases of
      hyperfibrinolysis or defective hemostasis diseases. It's major indications are prostatic
      surgery and menorrhagia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>volume of intraoperative bleeding</measure>
    <time_frame>one day</time_frame>
    <description>intraoperative bleeding (in mL of aspirated blood) measured at the end of the surgical procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of postoperative bleeding</measure>
    <time_frame>ten days</time_frame>
    <description>incidence of oral bleeding at the ten days after surgery, evaluated by a patient's diary and postoperative medical evaluations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Tonsillectomy</condition>
  <condition>Adenoidectomy</condition>
  <condition>Tranexamic Acid</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>10mg/Kg, IV (in the vein), first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <other_name>Transamin</other_name>
    <other_name>Hemoblock</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>normal saline solution</intervention_name>
    <description>normal saline solution in the same volume calculated as treatment (tranexamic acid 250mg/mL, 10mg/Kg), IV (in the vein) first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children with 4 to 12 years

          -  adenotonsillar hypertrophy

          -  indication of adenotonsillectomy

        Exclusion Criteria:

          -  patients with blood dyscrasia

          -  patients with history of bleeding of difficult control or spontaneous hematoma

          -  patients with coagulation tests altered

          -  patients with evidence of hematopoietic, cardiovascular, hepatic, renal, neurologic,
             psychiatric or auto immune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marília R Brum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Irmandade Santa Casa de Misericórdia de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Faibes Lubianca Neto, MD</last_name>
    <role>Study Director</role>
    <affiliation>Irmandade Santa Casa de Misericórdia de Porto Alegre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital da Criança Santo Antônio</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035-074</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2010</study_first_submitted>
  <study_first_submitted_qc>October 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2010</study_first_posted>
  <last_update_submitted>December 21, 2010</last_update_submitted>
  <last_update_submitted_qc>December 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Marília Ribeiro Brum</name_title>
    <organization>Irmandade Santa Casa de Misericórdia de Porto Alegre</organization>
  </responsible_party>
  <keyword>Adenotonsillectomy</keyword>
  <keyword>Tranexamic acid</keyword>
  <keyword>Blood loss</keyword>
  <keyword>Postoperative hemorrhage</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

